Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 15Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 41CNS 18Lymphoid 12Genitourinary 12Gastrointestinal 11Myeloid 8Dermatologic 7Endocrine 3Breast 3Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 173Head and Neck Neoplasms 140Thyroid Neoplasms 59Carcinoma, Non-Small-Cell Lung 58Oropharyngeal Neoplasms 48Melanoma 47Nasopharyngeal Carcinoma 45Colorectal Neoplasms 33Mouth Neoplasms 30Carcinoma, Renal Cell 29Breast Neoplasms 27Uterine Cervical Neoplasms 26Neoplasms 26Ovarian Neoplasms 25Stomach Neoplasms 24Carcinoma, Squamous Cell 23Lung Neoplasms 22Esophageal Neoplasms 22Triple Negative Breast Neoplasms 20Neoplasm Metastasis 20Endometrial Neoplasms 20Salivary Gland Neoplasms 19Thyroid Cancer, Papillary 16Pancreatic Neoplasms 16Sarcoma 15Laryngeal Neoplasms 15Urinary Bladder Neoplasms 13Prostatic Neoplasms 13Colonic Neoplasms 13Carcinoma, Transitional Cell 13

Interventions

tipifarnib 1fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Osteosarcoma × Head & Neck × Clear all
NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡